PEG core cross-linked star-shaped polymer nano-contrast agent and its preparation method and application
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A nano-contrast agent and polymer technology, which is applied in the direction of non-active ingredients medical preparations, pharmaceutical formulas, preparations for in vivo tests, etc.
Active Publication Date: 2021-10-29
SHANGHAI TENTH PEOPLES HOSPITAL
View PDF6 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
In the prior art, there is no report about the PEG nuclear cross-linked star-shaped polymer nano-contrast agent used for fundus angiography of the present invention.
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0039] Example 1PEG nuclear cross-shaped polymer nanometric film preparation
[0040] Material
[0041] Polyethylene glycol methyl methacrylate (PPEGMA, M n = 300), Sigma-Aldrich, Item No .: 447935; 2-cyano-2-propylodaryyl trikarcarbonate (CTA), Sigma-Aldrich, Item No .: 723037; 1,4-dioxane, Chinese medicine, product number: 10008918; 2,2'-azo bis (2-methylproprionne) (AIBN, CP), Aladdin, Item No.: A104256; 2,2'-azo double (2-methylpropen) ))) Salts (V-50, 97%), Sigma-Aldrich, Item No .: 440914; N, N'-Double (acryl) cystamine (BAC, 98%), Alfa Aesar, Item No .: A-4929 . BN rats were purchased in Beijing Virong Lihua Experimental Animal Technology Co., Ltd., ICR mice were purchased from Shanghai Slack Experimental Animal Co., Ltd. ARPE-19 cell lines from ICELL BIOSCIENCE; human umbilical vein endothelial cells Purchased from Scientll, ICG Amine, purchased from AAT Bioquest, Item No .: 188; Cell Activity Detection Kit (CCK-8) Purchased from Yeasen, Item No .: 40203ES60; Hydrochloride...
Embodiment 2
[0058] Example 2S-PPEGMA 10 -ICG verification of safety and effectiveness of cells and animal levels
[0059] Material, method
[0060] 1.1CCK8 experiment
[0061] Take the several long-term Arpe-19 and huvec cells, laying 96-well plates with 5,000 / well, and placed in the incubator for 24 h, and to be cellular. Add 0-400 nmol / L ICG and S-PPEGMA separately 10 -ICG, incubated 24h. Incubate, each well contains 10 ul CCK-8 medium 110 ul, 37 ° C incubator, and incubation for 2 h. At the end of the detection, the wavelength of 450 nm was selected, and the OD values of each well were detected on the multi-functional enzyme instrument.
[0062] 1.2 Flow cytometry
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention relates to a PEG core cross-linked star-shaped macromolecule nano-contrast agent. The contrast agent is a star-shaped macromolecule with PEG as the core and is prepared by bonding a fluorescent group. The invention also relates to the application of the PEG core cross-linked star-shaped macromolecule nano-contrast material in the preparation of fundus vascular contrast agent. Fundus angiography currently used clinically, such as sodium fluorescein or indocyanine green, has adverse reactions when intravenous contrast agents are injected in some patients, and these patients cannot complete the angiography examination. Compared with existing contrast agents, S-PPEGMA of the present invention 10 ‑ICG has the advantages of lower injection concentration and clearer choroid visualization, which can reduce the side effects of the original drug by reducing the administration concentration. In addition, S‑PPEGMA 10 ‑The successful construction of ICG also provides another option for patients who have allergies or other adverse reactions to the injection of existing contrast agents, so that patients can be diagnosed and treated in a timely manner.
Description
Technical field [0001] The present invention relates to the field of fundamental angiography, in particular, is a PEG nuclear cross-strand polymer nano-contrast agent and a preparation method thereof. Background technique [0002] Age-Related Macular Degeneration (AMD) is one of the most important reasons for the central vision of the old people over the age of 50, and there is currently 21 million AMD patients around the world. AMD is divided into dry and wettable based on its non-resinite. Early dry AMD appears to be glass film, and the vision is not serious. It has developed to the late stage, and there will be atrophy in the late stage, and there will be atrophy. Wet AMD, due to the emergence of choroidal neovascularization, CNV), causing bleeding, edema, and severe vision due to hemorrhous bleeding, edema, and vision. At present, the diagnostic methods of AMD include: eye base photography, OCT, fundamental angiography technology, where the eye angiography technology plays an...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more